Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors

Pediatric Blood and Cancer

Volumn 58, Issue 3, 2012, Pages 372-379

  Mcgregor, Lisa M ^a,b   Stewart, Clinton F ^a   Crews, Kristine R ^a   Tagen, Michael ^a,c   Wozniak, Amy ^a,d   Wu, Jianrong ^a   Mccarville, M Beth ^a   Navid, Fariba ^a,b   Santana, Victor M ^a,b   Houghton, Peter J ^b,e   Furman, Wayne L ^a,b   Rodriguez Galindo, Carlos ^a,b,f  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d Meridian Healthcare   (United States)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adolescent; Cephalosporin; Child; Clinical trial, phase I; Irinotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CEFIXIME; CEFPODOXIME; CEPHALOSPORIN; IRINOTECAN; TEMOZOLOMIDE; VINCRISTINE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BONE PAIN; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CHORDOMA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; ERYTHROCYTE CONCENTRATE; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; PARAGANGLIOMA; PERIPHERAL NERVE TUMOR; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CEFTIZOXIME; CHILD; CHILD, PRESCHOOL; DIARRHEA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; TOPOISOMERASE I INHIBITORS; YOUNG ADULT;

EID: 84862908405     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23075     Document Type: Article

References (53)

1. Houghton PJ, Cheshire PJ, Hallman JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393-403.
2. Jansen WJ, Kolfschoten GM, Erkelens CA, et al. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Int J Cancer 1997; 73: 891-896.
3. Pawlik CA, Houghton PJ, Stewart CF, et al. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin Cancer Res 1998; 4: 1995-2002.
4. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997; 3: 423-431.
5. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998; 90: 505-511.
6. Houghton PJ, Cheshire PJ, Myers L, et al. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992; 31: 229-239.
7. Vassal G, Boland I, Santos A, et al. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 1997; 73: 156-163.
8. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999; 17: 1815-1824.
9. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol 2007; 25: 362-369.
10. Akimoto K, Kawaii M, Ohya K. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives. Chemother Pharmacol Bull 1994; 42: 2135-2138.
11. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854.
12. Kaneda N, Nagata H, Furuta T, et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715-1720 [published erratum appears in Cancer Res. 1990; Jul 15;50(14):4451].
13. Takasuna K, Hagiwara T, Hirohashi M, et al. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 1998; 42: 280-286.
14. Takasuna K, Hagiwara T, Watanabe K, et al. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea. Cancer Chemother Pharmacol 2006; 58: 494-503.
15. Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7: 1136-1141.
16. Alimonti A, Satta F, Pavese I, et al. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 2003; 14: 805-806.
17. Furman WL, Crews KR, Billups C, et al. Cefixime allows greater dose escalation of oral irinotecan: A phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 2006; 24: 563-570.
18. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004; 10: 840-848.
19. Common Terminology Criteria (CTC) version 2.0. Cancer Therapy Evaluation Program. 4-30- 1999. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD. Ref Type: Electronic Citation.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
21. Crews KR, Stewart CF, Jones-Wallace D, et al. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 2002; 8: 2202-2209.
22. Bisogno G, Riccardi R, Ruggiero A, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006; 106: 703-707.
23. Shitara T, Shimada A, Tsuchida Y, et al. Successful clinical response to irinotecan in relapsed neuroblastoma. Med Pediatr Oncol 2003; 40: 126-128.
24. Wagner LM, Crews KR, Stewart CF, et al. Reducing irinotecan-associated diarrhea in children. Pediatr Blood Cancer 2008; 50: 201-207.
25. Desai AA, Kindler HL, Taber D, et al. Modulation of irinotecan with cyclosporine: A phase II trial in advanced colorectal cancer. Cancer Chemother Pharmacol 2005; 56: 421-426.
26. Michael M, Brittain M, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004; 22: 4410-4417.
27. Karthaus M, Ballo H, Abenhardt W, et al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005; 68: 326-332.
28. Govindarajan R, Heaton KM, Broadwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000; 356: 566-567.
29. Savarese D, Al Zoubi A, Boucher J. Glutamine for irinotecan diarrhea. J Clin Oncol 2000; 18: 450-451.
30. Delioukina ML, Prager D, Parson M, et al. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer 2002; 94: 2174-2179.
31. Mori K, Kondo T, Kamiyama Y, et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 51: 403-406.
32. Sergio GC, Felix GM, Luis JV. Activated charcoal to prevent irinotecan-induced diarrhea in children. Pediatr Blood Cancer 2008; 51: 49-52.
33. McGregor LM, Spunt SL, Furman WL, et al. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: A Children's Oncology Group study. Cancer 2009; 115: 1765-1775.
34. McNall-Knapp RY, Williams CN, Reeves EN, et al. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. Pediatr Blood Cancer 2010; 54: 909-915.
35. Vollaard EJ, Clasener HA. Colonization resistance. Antimicrob Agents Chemother 1994; 38: 409-414.
36. Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 1973; 32: 1490-1498.
37. Patrick CC. Use of fluoroquinolones as prophylactic agents in patients with neutropenia. Pediatr Infect Dis J 1997; 16: 135-139.
38. Neomycin sulfate tablet [X-GEN Pharmaceuticals, Inc.]. Daily Med. 2010. National Library of Medicine (US). 6-9-2010. Ref Type: Electronic Citation.
39. Knothe H, Shah PM, Eckardt O. Cefpodoxime: Comparative antibacterial activity, influence of growth conditions, and bactericidal activity. Infection 1991; 19: 370-376.
40. McBain AJ, Macfarlane GT. Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites. J Med Microbiol 1998; 47: 407-416.
41. Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 2010; 54: 538-545.
42. Wagner LM, Villablanca JG, Stewart CF, et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: A new approach to neuroblastoma therapy consortium study. J Clin Oncol 2009; 27: 1290-1296.
43. Deeken JF, Slack R, Marshall JL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: To test or not to test, that is the question. Cancer 2008; 113: 1502-1510.
44. Del BG, Lassota P, Darzynkiewicz Z. The S-phase cytotoxicity of camptothecin. Exp Cell Res 1991; 193: 27-35.
45. Mascarenhas L, Lyden ER, Breitfeld PP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 2010; 28: 4658-4663.
46. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 2001; 7: 32-37.
47. Bagatell R, London WB, Wagner LM, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A children's oncology group study. J Clin Oncol 2011; 29: 208-213.
48. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007; 48: 132-139.
49. Aguilera DG, Goldman S, Fangusaro J. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. Pediatr Blood Cancer 2011; 56: 491-494.
50. Gururangan S, Chi SN, Young PT, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28: 3069-3075.
51. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52: 791-795.
52. Furman WL, Navid F, Daw NC, et al. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol 2009; 27: 4599-4604.
53. Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: A study of the pediatric oncology experimental therapeutic investigators' consortium. J Clin Oncol 2009; 27: 5102-5108.